Clinical Trials

CREATE-1 Type 1 Diabetes

Creative Medical Technology Holdings, Inc. focuses on developing regenerative medicine & immunotherapies that seek to improve patient outcomes & quality of living.

Type 1 Diabetes

Type 1 diabetes is a chronic autoimmune disease leading to the destruction of insulin producing cells within the pancreas. Autoreactive T cells and abnormalities in immune regulation, especially in regulatory T cells, are thought to play a key role in disease development. Chronic autoimmune T cell attacks against the pancreatic cells are considered the primary cause of type 1 diabetes. These attacks on pancreatic cells lead to the loss of the ability to produce insulin and in turn creates a life-long dependence on insulin injections.

Is there A Cure For Type 1 Diabetes?

There currently is no cure for type 1 diabetes. The disease is treated with regular insulin injections and close blood glucose monitoring. Despite the advances in insulin therapy, many patients still suffer from hypo- and hyperglycemia. Also, insulin therapy can potentially be very expensive, making it an even more difficult disease to manage.

Who it Impacts

In the United States alone, approximately 1.3 million people, especially children and adolescents, suffer from type 1 diabetes. The incidence of type 1 diabetes continues to increase in many countries. The disease severely impacts quality of life and leads to both acute and chronic complications, such as end stage renal disease, blindness, cardiovascular disease, diabetic ketoacidosis and hypoglycemia. The economic burden caused by type 1 diabetes amounts to approximately $14.4 billion in medical costs and lost income.

For more information, click here

Type 1 Diabetes Clinical Trial

The values that drive everything we do

01

Innovation

At mi nunc ullamcorper semper purus libero etiam eget faucibus netus ut purus sit at volutpat morbi pellentesque velit enim nibh odio sed vel dui magna id tincidunt lorem

02

Ownership

Pellentesque at ultrices diam ut enim massa purus pellentesque diam elementum ut massa habitant tortor enim aliquam tristique a ornare diam mi sed ut sem cras tortor

03

Growth

Sed non imperdiet montes massa feugiat duis scelerisque pretium nulla vitae quisque turpis ultricies consequat vulputate ut morbi dui maecenas nunc arcu nulla enim nam et

04

Teamwork

Aliquam nibh id fringilla enim quis fermentum malesuada sit mi lectus ultrices velit scelerisque accumsan ullamcorper egestas sit nulla amet ut facilisis ut tortor at amet vel

05

Growth

Consequat turpis diam posuere elementum molestie at augue id massa curabitur sed in rhoncus elit vitae ipsum neque aliquet vulputate at iaculis turpis eu mauris

06

Passion

Nunc sem lectus diam venenatis amet diam sed blandit lorem est gravida mauris sit cursus eu vestibulum adipiscing ac molestie ut neque adipiscing eget cras semper

Learn More About The CELZ-201 Trial